Keyphrases
Tumor
76%
Overall Survival
60%
Chemotherapy
47%
Acute Myeloid Leukemia
47%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
44%
Phase II Study
43%
Confidence Interval
41%
Multiple Myeloma
38%
Breast Cancer
36%
Progression-free Survival
35%
Phase II Trial
34%
Non-small Cell Lung Cancer (NSCLC)
33%
Relapsed or Refractory
30%
Granulocyte Colony-stimulating Factor (G-CSF)
28%
T Cells
27%
Hematopoietic Stem Cells
27%
In Cancer
27%
Clinical Trials
27%
Graft-versus-host Disease (GvHD)
24%
Leukemia
23%
Natural Killer Cells
23%
Rituximab
22%
Hazard Ratio
21%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
21%
Bone Marrow
20%
Targeted Therapy
18%
Human Immunodeficiency Virus Type 1 (HIV-1)
18%
Metastatic Breast Cancer
18%
Non-Hodgkin Lymphoma
17%
Myelodysplastic Syndrome
17%
Clinical Outcomes
17%
Adverse Events
17%
Lung Cancer
17%
Diffuse Large B-cell Lymphoma (DLBCL)
16%
Mantle Cell Lymphoma
16%
Lymphoma
16%
Gene Expression
15%
NCCN Guidelines
15%
Follicular Lymphoma
15%
Doxorubicin
15%
Older Adults
14%
Pancreatic Cancer
14%
Triple-negative Breast Cancer
14%
High Risk
14%
Overall Response Rate
14%
Tumor Cells
14%
Complete Response
14%
Radiation Therapy
14%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
14%
Gemcitabine
13%
Cyclophosphamide
13%
Median Overall Survival
13%
Oncology
13%
Partial Response
13%
Macrophages
13%
Hematological Malignancies
13%
Solid Tumors
13%
Brentuximab Vedotin
13%
Placebo
13%
Chimeric Antigen Receptor T Cells (CAR-T)
13%
Programmed Death-ligand 1 (PD-L1)
12%
Lenalidomide
12%
Cisplatin
12%
Melanoma
12%
Phase I Study
12%
Malignancy
12%
Disease Progression
12%
Hodgkin Lymphoma
12%
Clear Cell Renal Cell Carcinoma (ccRCC)
12%
Docetaxel
12%
Hematopoietic Cell Transplantation
11%
Colorectal Cancer
11%
Bortezomib
11%
Prostate Cancer
11%
Next-generation Sequencing
11%
Pancreatic Ductal Adenocarcinoma
11%
Somatic mutation
11%
Transplantation
11%
Cancer Types
11%
Older Patients
11%
Median Progression-free Survival
11%
Human Epidermal Growth Factor Receptor 2 (HER2)
11%
Newly Diagnosed
11%
Complete Remission
11%
Neutropenia
11%
Monotherapy
11%
Response Rate
11%
Mouse Model
10%
Paclitaxel
10%
Tumor Growth
10%
Apoptosis
10%
Randomized Phase II Trial
10%
Genetic Modification
10%
Carboplatin
10%
Relapsed or Refractory multiple Myeloma
10%
Metastasis
10%
Glioblastoma
10%
Tumor Microenvironment
10%
Pembrolizumab
10%
Immune Checkpoint Inhibitors
10%
Medicine and Dentistry
Neoplasm
100%
Diseases
72%
Malignant Neoplasm
68%
Overall Survival
60%
Breast Cancer
53%
Hematopoietic Cell
38%
Multiple Myeloma
35%
Progression Free Survival
34%
Acute Myeloid Leukemia
32%
Cancer
31%
Clinical Trial
31%
Non Small Cell Lung Cancer
29%
Oncology
28%
Metastatic Carcinoma
25%
Immunotherapy
24%
T Cell
23%
Radiation Therapy
22%
Transplantation
20%
Cell Transplantation
20%
Adverse Event
20%
Lung Cancer
19%
Arm
19%
Biological Marker
19%
Rituximab
18%
Non-Hodgkin Lymphoma
18%
Targeted Therapy
18%
Leukemia
17%
Hazard Ratio
16%
Hodgkin's Lymphoma
16%
Recurrent Disease
15%
Melanoma
14%
Diffuse Large B-Cell Lymphoma
14%
Prostate Cancer
14%
Mantle Cell Lymphoma
14%
Myelodysplastic Syndrome
14%
Immunity
14%
Surgery
14%
Clear Cell Renal Cell Carcinoma
14%
Pancreas Cancer
12%
Tumor Progression
11%
Pancreas Adenocarcinoma
11%
Metastatic Breast Cancer
11%
Cancer Cell
11%
B Cell
11%
Human Immunodeficiency Virus
10%
Follicular Lymphoma
10%
Hematopoiesis
10%
Solid Malignant Neoplasm
10%
Doxorubicin
10%
Tumor Cell
10%
Placebo
10%
Connective Tissue Cancer
10%
Cancer Therapy
10%
Granulocyte Colony Stimulating Factor
10%
Triple Negative Breast Cancer
10%
Stem Cell
9%
Phase II Trials
9%
Pembrolizumab
9%
Cisplatin
9%
Colorectal Carcinoma
9%
In Vitro
9%
Positron Emission Tomography
9%
Systemic Therapy
9%
Cyclophosphamide
9%
Diagnosis
9%
Paclitaxel
9%
Brentuximab Vedotin
9%
Lenalidomide
8%
Quality of Life
8%
Acute Lymphoblastic Leukemia
8%
Gemcitabine
8%
Macrophage
8%
Hematologic Malignancy
8%
Drug Megadose
8%
Stem Cell Transplant
8%
Systematic Review
8%
Immune Checkpoint Inhibitor
8%
Small Cell Lung Cancer
8%
Xenograft
7%
Receptor
7%
Hormone Therapy
7%
Chemoradiotherapy
7%
B-Cell Chronic Lymphocytic Leukemia
7%
Peripheral T-Cell Lymphoma
7%
Bortezomib
7%
Next Generation Sequencing
7%
Neutropenia
7%
Natural Killer Cell
7%
Soft Tissue Sarcoma
7%
Circulating Tumor DNA
7%
Chimeric Antigen Receptor T-Cell
7%
Epidermal Growth Factor Receptor
7%
Infection
7%
Health Care Cost
7%
Gene Expression
7%
Hematopoietic Stem Cell Transplantation
7%
Disease Free Survival
7%
Glioblastoma
7%
Graft Versus Host Reaction
7%
Gene Mutation
6%